To further investigate the role of GSTZ1 in mediating sorafenib resistance in HCC progression in vivo, we established the mouse model of liver cancer induced by DEN/CCl4 as described previously20 and drug administration with three regimens: DMSO, sorafenib (30 mg/kg, every 2 days for 4 weeks), RSL3 (10 mg/kg, every 2 days for 4 weeks) (Fig. 7A). This evidence concerns the gene GSTZ1 and liver cancer.